Table 3. Multivariable Cox proportional hazards model for concurrent vs sequential treatment based on overall survival (stratified by performance status, PSA response to previous therapy and bone scan)a.
| Characteristic | Hazard ratio (95% CI)b | P-value |
|---|---|---|
| Age (in years) | 0.70 (0.49–1.00) | 0.051 |
| Age square | 1.0025 (1.00049–1.00502) | 0.046 |
| Treatment | 0.16 | |
| DAdS | 1 | |
| DAiS | 0.69 (0.41–1.16) | |
| Haemoglobin | 0.004 | |
| <11 g dl−1 | 1 | |
| ⩾11 g dl−1 | 0.44 (0.25–0.77) | |
| Alkaline phosphatase | 0.93 | |
| <1.5 × ULN | 1 | |
| ⩾1.5 × ULN | 0.97 (0.55–1.71) | |
| Gleason | 0.49 | |
| ⩽6 | 1 | |
| 7 | 0.82 (0.40–1.71) | |
| 8–10 | 0.68 (0.35–1.30) | |
| Prior therapy | 0.01 | |
| GnRH | 1 | |
| AA | 5.38 (1.99–14.58) | |
| MAB | 1.91 (0.90–4.07) | |
| Radical treatment (radiotherapy or surgery) | 1.38 (0.76–2.50) | |
| Diabetes | 0.44 | |
| Absent | 1 | |
| Present | 0.68 (0.25–1.81) | |
| Myocardial infarction | 0.13 | |
| Absent | 1 | |
| Present | 2.07 (0.81–5.27) | |
| Respiratory disease | 0.44 | |
| Absent | 1 | |
| Present | 0.73 (0.33–1.62) |
Abbreviations: AA=anti-androgen; DAiS=Dexamethasone, Aspirin, and immediate addition of Diethylstilbestrol; DAdS=Dexamethasone, Aspirin, and deferred (until disease progression) Diethylstilbestrol; CI=confidence interval; GNRH=gonadorelin analogues; MAB=maximum androgen blockade; PSA=prostate-specific antigen; ULN=upper limit of normal.
a
Analysis was restricted to patients without missing values (n=164).
b
Hazard ratios are adjusted for all variables displayed in the table.